GSK pens $2.5B pact for ABL Bio’s tech to help antibodies bypass blood-brain barrier

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. | GSK has continued to flesh out its neuroscience strategy with a 2 billion pound ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier.Read More